[go: up one dir, main page]

UA111520C2 - [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази - Google Patents

[1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази

Info

Publication number
UA111520C2
UA111520C2 UAA201408124A UAA201408124A UA111520C2 UA 111520 C2 UA111520 C2 UA 111520C2 UA A201408124 A UAA201408124 A UA A201408124A UA A201408124 A UAA201408124 A UA A201408124A UA 111520 C2 UA111520 C2 UA 111520C2
Authority
UA
Ukraine
Prior art keywords
phosphodiesterase inhibitors
triazolopyridine compounds
triazolopyridine
compounds
phosphodiesterase
Prior art date
Application number
UAA201408124A
Other languages
English (en)
Russian (ru)
Inventor
Сімон Фельдбек Нільсен
Йєнс Хрістіан Хойланн Ларсен
Original Assignee
Лео Фарма А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лео Фарма А/С filed Critical Лео Фарма А/С
Publication of UA111520C2 publication Critical patent/UA111520C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Даний винахід стосується нових похідних [1,2,4]триазолопіридину з інгібуючою фосфодіестеразу активністю, а також їх застосування як терапевтичних агентів при лікуванні запальних захворювань і станів.
UAA201408124A 2011-12-21 2012-12-19 [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази UA111520C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161578677P 2011-12-21 2011-12-21
US201261666430P 2012-06-29 2012-06-29
PCT/EP2012/076191 WO2013092739A1 (en) 2011-12-21 2012-12-19 [1,2,4]triazolopyridines and their use as phospodiesterase inhibitors

Publications (1)

Publication Number Publication Date
UA111520C2 true UA111520C2 (uk) 2016-05-10

Family

ID=47429831

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201408124A UA111520C2 (uk) 2011-12-21 2012-12-19 [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази

Country Status (20)

Country Link
US (2) US8940761B2 (uk)
EP (1) EP2794603B1 (uk)
JP (1) JP6138150B2 (uk)
KR (1) KR20140105598A (uk)
CN (1) CN104011048B (uk)
AU (1) AU2012357106A1 (uk)
BR (1) BR112014014802A2 (uk)
CA (1) CA2858123A1 (uk)
ES (1) ES2583478T3 (uk)
HK (1) HK1200815A1 (uk)
IL (1) IL232712A (uk)
MX (1) MX2014006812A (uk)
PL (1) PL2794603T3 (uk)
PT (1) PT2794603T (uk)
RU (1) RU2630699C2 (uk)
SG (1) SG11201402424PA (uk)
TW (1) TW201331202A (uk)
UA (1) UA111520C2 (uk)
WO (1) WO2013092739A1 (uk)
ZA (1) ZA201403649B (uk)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2585469T1 (sl) * 2010-06-24 2016-11-30 Leo Pharma A/S Heterociklične spojine benzodioksola ali benzodioksepina kot zaviralci fostodiesteraze
WO2014206903A1 (en) * 2013-06-25 2014-12-31 Leo Pharma A/S METHODS FOR THE PREPARATION OF SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIDINES
DK3642210T3 (da) 2017-06-20 2024-12-09 Union Therapeutics As Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
CN111712502B (zh) * 2017-12-15 2023-10-27 联合疗法公司 取代的氮杂环丁烷二氢噻吩并嘧啶类化合物及其作为磷酸二酯酶抑制剂的用途
EP3724196B9 (en) 2017-12-15 2023-03-22 UNION therapeutics A/S Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
GB202306662D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU705690B2 (en) 1995-05-19 1999-05-27 Kyowa Hakko Kogyo Co. Ltd. Oxygen-containing heterocyclic compounds
WO1998022455A1 (en) 1996-11-19 1998-05-28 Kyowa Hakko Kogyo Co., Ltd. Oxygenic heterocyclic compounds
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
US20080248958A1 (en) * 2007-04-05 2008-10-09 Hollenbach Andrew D System for pulling out regulatory elements in vitro
ATE540037T1 (de) 2007-04-16 2012-01-15 Leo Pharma As Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten
EP2200394B1 (en) * 2008-12-19 2012-08-15 Rtx A/S Cell for self-configuring wireless communication network
US8952162B2 (en) 2008-12-19 2015-02-10 Leo Pharma A/S Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
EP2563770B1 (en) * 2010-04-28 2016-03-23 Leo Pharma A/S Biaryl phosphodiesterase inhibitors

Also Published As

Publication number Publication date
JP2015502381A (ja) 2015-01-22
WO2013092739A1 (en) 2013-06-27
EP2794603A1 (en) 2014-10-29
MX2014006812A (es) 2014-10-13
EP2794603B1 (en) 2016-06-15
ES2583478T3 (es) 2016-09-21
JP6138150B2 (ja) 2017-05-31
SG11201402424PA (en) 2014-09-26
CA2858123A1 (en) 2013-06-27
IL232712A0 (en) 2014-08-03
KR20140105598A (ko) 2014-09-01
ZA201403649B (en) 2016-05-25
BR112014014802A2 (pt) 2017-06-13
CN104011048A (zh) 2014-08-27
TW201331202A (zh) 2013-08-01
US9181248B2 (en) 2015-11-10
NZ625849A (en) 2016-06-24
PL2794603T3 (pl) 2017-08-31
PT2794603T (pt) 2016-07-26
RU2014129514A (ru) 2016-02-10
US8940761B2 (en) 2015-01-27
CN104011048B (zh) 2017-03-15
US20150105420A1 (en) 2015-04-16
AU2012357106A1 (en) 2014-06-05
IL232712A (en) 2016-06-30
RU2630699C2 (ru) 2017-09-12
HK1200815A1 (en) 2015-08-14
US20140329853A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
MX336381B (es) Boronatos como inhibidores de arginasa.
IN2014DN07384A (uk)
TN2014000128A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
PH12015501964B1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
JO3002B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
MX364486B (es) Derivados de piridazinona-amidas.
MX366318B (es) Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1.
MD4601B1 (ro) Inhibitor al kinazei inductoare de apoptoză
PH12013501758A1 (en) Pyrazolo [1,5-a] pyridines as trk inhibitors
MX349004B (es) Nuevos compuestos.
IN2014DN09434A (uk)
MX2014002683A (es) Derivados de benzonitrilo como inhibidores de cinasa.
TN2013000325A1 (en) (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases
MX2014002393A (es) Inhibidores de rock suaves, novedosos.
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
SI2771329T1 (sl) Nove disubstituirane 3,4-diamino-3-ciklobuten-1,2-dion-spojine za uporabo pri tretiranju kemokin mediiranih bolezni
PH12012502070A1 (en) Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
AU2012307449A8 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions